Medicinal Products (Control of Manufacture) Regulations 2007 (Amendment) Regulations 2009
Statutory Instruments
Source: Statutory Instruments

num: 1
paragraphs: These Regulations may be cited as the Medicinal Products (Control of Manufacture) Regulations 2007 (Amendment) Regulations 2009.
num: 2
paragraphs: These Regulations shall be construed as one with the Medicinal Products (Control of Manufacture) Regulations 2007 ( S.I. No. 539 of 2007 ) and may be cited together with those Regulations as the Medicinal Products (Control of Manufacture) Regulations 2007 and 2009.
num: 3
paragraphs: These Regulations shall come into force on 14 January 2009.
num: 4
paragraphs: (1) In these Regulations:
num: 5
paragraphs: Regulation 3(1) of the principal regulations is amended—
(a) by inserting the following before the definition of “Act”:
“ ‘advanced therapy medicinal product’ means a product as defined in Article 2 of the advanced therapy regulation;
‘advanced therapy regulation’ means Regulation (EC) No. 1394/2007 of the European Parliament and of the Council of 13 November 2007 on advanced therapy medicinal products 16 ;”
(b) by substituting the following for the definition of “2001 Directive”:
“ ‘2001 Directive’ means Directive 2001/83/EC of the European Parliament and of the Council on the Community code relating to medicinal products for human use 17 as amended by—
(a) Directive 2002/98/EC of the European Parliament and of the Council setting standards of quality and safety for the collection, testing, processing, storage and distribution of human blood and blood components 18 ,
(b) Commission Directive 2003/63/EC amending Directive 2001/83/EC on the Community code relating to medicinal products for human use 19 ,
(c) Directive 2004/24/EC of the European Parliament and of the Council amending, as regards traditional herbal medicinal products, Directive 2001/83/EC on the Community code relating to medicinal products for human use 20 ,
(d) Directive 2004/27/EC of the European Parliament and of the Council amending Directive 2001/83/EC on the Community code relating to medicinal products for human use 21 , and
(e) the advanced therapy regulation;”;
num: 6
paragraphs: Schedule 2 to the principal regulations is amended by the insertion of the following after paragraph 31:
“32. (1) The authorisation holder, in the case of an advanced therapy medicinal product, shall establish and maintain a system ensuring that the individual product and its starting and raw materials, including all substances coming into contact with the cells or tissues it may contain, can be traced through the sourcing, manufacturing, packaging, storage, transport and delivery to the hospital, institution or private practice where the product is used.
(2) Where an authorisation holder manufactures an advanced therapy medicinal product that contains human cells or tissues, he or she shall ensure that the traceability systems established in accordance with paragraph 1 are complementary to, and compatible with, the requirements laid down in Articles 8 and 14 of Directive 2004/23/EC as regards human cells and tissues other than blood cells, and Articles 14 and 24 of Directive 2002/98/EC 22 as regards human blood cells.
(3) The authorisation holder shall keep the data referred to in subparagraph (1) for a minimum of 30 years after the expiry date of the product.
(4) In case of bankruptcy or liquidation of the authorisation holder who has manufactured an advanced therapy medicinal product, and in the event that the manufacturing authorisation is not transferred to another legal entity, the data referred to in paragraph (1) shall be transferred to the Board.
(5) In the event that the manufacturing authorisation is suspended, revoked or withdrawn, the holder of the manufacturing authorisation shall remain subject to the obligations laid down in paragraphs (1), (2) and (3).
(6) Subparagraphs (3) to (5) shall not apply to an authorisation holder where the holder of a marketing authorisation for the relevant advanced therapy medicinal product is, by virtue of such marketing authorisation, responsible for the retention of such data.
33. In paragraphs 2(c), 19, 20 and 23(1)(b) and (c), every reference to a medicinal product shall be a reference to a medicinal product that is intended to be placed on the market in the State or in another EEA State.”.
num: 7
paragraphs: Schedule 3 to the principal regulations is amended—
(a) by the substitution of the following for paragraph 25(4):
“(4) The authorisation holder shall not issue any advertisement, other than one that states only the trade name, pack size, price and dose, relating to an exempt medicinal product or make any representations in respect of such product.”;
(b) by the insertion of the following after paragraph 25:
“26. In paragraphs 2(g), 3, 12(1)(b) and (c) and 14, every reference to a medicinal product shall be a reference to a medicinal product that is intended to be placed on the market in the State or in another EEA State.”.
16 OJ No. L 324, 10.12.2007, p.121
17 OJ No. L. 311, 28.11.2001, p.67.
18 OJ No. L. 33, 08.02.2003, p.30.
19 OJ No. L. 159, 27.06.2003, p.46.
20 OJ No. L. 136, 30.04.2004, p.85.
21 OJ No. L. 136, 30.4.2004, p.34.
22 OJ No. L. 93, 8.2.2003, p.30.